№ files_lp_3_process_7_040864
File format: docx
Character count: 42569
File size: 252 KB
This document provides the updated protocol for examining resection specimens from patients with primary malignant bone tumors, intended for accreditation purposes under the CAP Laboratory Accreditation Program.
Year:
2024
Region / City:
N/A
Topic:
Medical protocol
Document Type:
Protocol
Organization / Institution:
CAP Laboratory Accreditation Program
Authors:
Julie C. Fanburg-Smith, MD, FCAP; Paari Murugan, MD, FCAP; Andrew Horvai, MD, PhD; Fernanda Amary, MD, PhD; Meera Hameed, MD, FCAP; Michael J. Klein, MD.
Target Audience:
Pathologists, medical professionals in oncology
Effective Period:
March 2025
Approval Date:
June 2024
Date of Changes:
June 2024
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Version:
4.4.0.0
Protocol Posting Date:
June 2021
CAP Laboratory Accreditation Program Protocol Required Use Date:
March 2022
Authors:
Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Note:
Accreditation Requirements
Year:
2021
Region / City:
Global
Theme:
Oncology, Breast Cancer
Document Type:
Protocol
Organization / Institution:
CAP (College of American Pathologists)
Author:
Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Target Audience:
Medical professionals, pathologists
Period of Validity:
From March 2022
Date of Approval:
June 2021
Date of Changes:
June 2021
Year:
2024
Region / City:
Not specified
Subject:
Pathology, Oncology
Document Type:
Protocol
Organization / Institution:
CAP (College of American Pathologists)
Author:
Uma G. Krishnamurti, MD, PhD; Kimberly H. Allison, MD; Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Target Audience:
Pathologists, Medical Institutions
Period of Validity:
March 2025
Approval Date:
Not specified
Date of Last Change:
June 2024
Year:
2019
Region / city:
Not specified
Theme:
Oncology
Document type:
Clinical Protocol
Authors:
Erin Rudzinski, MD; Bruce Pawel, MD; Armita Bahrami, MD; M. John Hicks, MD
Target audience:
Healthcare professionals involved in pediatric oncology
Period of validity:
Not specified
Approval date:
Not specified
Date of modifications:
February 2019
Version:
4.2.1.0
Protocol Posting Date:
June 2025
CAP Laboratory Accreditation Program Protocol Required Use Date:
March 2026
Year:
2025
Region / City:
Not specified
Subject:
Renal cell carcinoma, nephrectomy, tumor classification
Document Type:
Protocol
Institution:
CAP (College of American Pathologists)
Author:
Paari Murugan, MD, FCAP*, Robert W. Allan, MD, FCAP*, Lara R. Harik, MD, FCAP*
Target Audience:
Pathologists, medical professionals involved in cancer diagnostics
Effective Period:
March 2026 onward
Approval Date:
June 2025
Revision Date:
Not specified
Year:
2016
Region / City:
Orlando, FL
Theme:
Biomechanics, Orthopaedics
Document Type:
Conference Paper
Organization / Institution:
Orthopaedic Research Society
Authors:
Sueyoshi T, Small SR, Elliot JB, Gibbs GE, Seale RB, Berend ME, Ritter MA
Target Audience:
Medical professionals, researchers in orthopaedics
Period of Activity:
March 5-8, 2016
Date of Approval:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
Southampton, UK
Topic:
Oesophago-gastric cancer, neoadjuvant therapy, cardiopulmonary exercise testing
Document Type:
Research Article
Institution:
University of Southampton, Southampton NIHR Biomedical Research Centre
Author:
Malcolm A West, William CA Baker, Saqib Rahman, Alicia Munro, Sandy Jack, Michael PW Grocott, Timothy J Underwood, Denny ZH Levett
Target Audience:
Medical professionals, oncologists, researchers
Period of Effectiveness:
Not specified
Approval Date:
Not specified
Date of Modifications:
Not specified
Version:
5.1.0.0
Protocol Posting Date:
September 2025
CAP Laboratory Accreditation Program Protocol Required Use Date:
June 2026
Note:
The changes included in this current protocol version affect accreditation requirements. The new deadline for implementing this protocol version is reflected in the above accreditation date.
Resection:
Includes pneumonectomy, lobectomy, segmentectomy, and wedge resection
Carcinoma:
Includes non-small cell carcinoma, small cell carcinoma, and carcinoid tumor of the lung
Year:
2025
Region / City:
Global
Theme:
Medical Protocol, Oncology
Document Type:
Protocol
Institution:
CAP (College of American Pathologists)
Author:
Frank Schneider, MD, Kirtee Raparia, MD, FCAP
Target Audience:
Medical professionals in pathology and oncology
Period of Validity:
2025-2026
Approval Date:
September 2025
Modification Date:
September 2025
Year:
2023
Region:
China
Subject:
Male rectal cancer, laparoscopic surgery, postoperative urogenital function
Document Type:
Clinical trial protocol
Organization:
Sun Yat-sen University, Multiple affiliated hospitals
Author:
Research Team
Target Audience:
Medical professionals, researchers, clinicians
Period of Action:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
Singapore
Theme:
Hepatocellular carcinoma, Surgical resection
Document type:
Meta-analysis
Author:
Aaron JL Lee, Andrew GR Wu, Kuo Chao Yew, Vishal G Shelat
Target audience:
Medical professionals, Researchers
Period of validity:
Not specified
Approval date:
February 1, 2023
Date of changes:
Not specified
Year:
2020
Protocol Version:
4.2.0.1
Protocol Posting Date:
February 2020
Required Use Date:
February 2020
Subject:
Primary carcinoma of the vagina
Procedure:
Resection (includes vaginectomy)
Tumor Types Included:
Squamous cell carcinoma, adenocarcinoma and variants, carcinosarcoma, neuroendocrine carcinoma, mixed epithelial–neuroendocrine tumors
Staging System:
pTNM (8th Edition, AJCC Staging Manual), 2018 FIGO Cancer Report
Issuing Organization:
College of American Pathologists
Program:
CAP Laboratory Accreditation Program
Committees:
CAP Cancer Committee; CAP Pathology Electronic Reporting Committee
Authors:
Saeid Movahedi-Lankarani, MD; Uma Krishnamurti, MD, PhD; Debra A. Bell, MD; George G. Birdsong, MD; Charles V. Biscotti, MD; Christopher N. Chapman Jr, MD; Dina H. Kandil, MD; Veronica Klepeis, MD, PhD; Anthony G. Montag, MD; Christopher N. Otis, MD
Document Type:
Cancer protocol and surgical pathology reporting guideline
Applicable Specimens:
Definitive primary cancer resection specimens
Exclusions:
Biopsy specimens; cytologic specimens; lymphoma; sarcoma; recurrent or metastatic tumors resected separately
Year:
2010–2022
Region / City:
Hyogo, Japan
Subject:
Biliary Tract Cancer, Sarcopenia, Surgical Outcomes
Document Type:
Clinical Study
Institution:
Meiwa Hospital, Department of Surgery
Authors:
Shinichi Ikuta, Tsukasa Aihara, Takayoshi Nakajima, Meidai Kasai, Naoki Yamanaka
Target Audience:
Oncologists, Surgeons, Clinical Researchers
Patient Cohort:
211 patients undergoing BTC resection
Primary Tumor Sites:
Intrahepatic bile duct, Extrahepatic bile duct, Gallbladder, Ampulla of Vater
Follow-up Method:
Disease-specific survival (DSS), Relapse-free survival (RFS)
Ethics Approval:
Institutional Ethics Committee of Meiwa Hospital, approval No. 2022-36
Year:
2021
Region / City:
Australia
Topic:
Healthcare, Medicare
Document Type:
Legislative Amendment
Organization:
Australian Department of Health
Author:
Medical Services Advisory Committee (MSAC)
Target Audience:
Specialist gastroenterologists, surgical endoscopists
Effective Period:
From 1 January 2022
Approval Date:
25 November 2021
Amendment Date:
N/A
Changes Description:
Amendments to MBS item 32230 for endoscopic mucosal resection (EMR) for large colorectal polyps
Related Legislation:
Guaranteeing Medicare – changes to the Medicare Benefit Schedule
Description:
Legislative amendment to clarify time frame for EMR service following diagnostic colonoscopy for specified colorectal polyp treatments.
Year:
2021
Organisation:
International Collaboration on Cancer Reporting
Document type:
Histopathology reporting guide
Subject:
Gastrointestinal stromal tumour (GIST)
Scope:
Pathology reporting of resection specimens for GIST
Exclusions:
Metastatic GIST specimens
Edition:
1st edition
Applicable staging system:
Pathological TNM staging
Evidence framework:
NHMRC levels of evidence
Intended users:
Pathologists reporting GIST resection specimens
Related publications:
Gastrointestinal Stromal Tumour (GIST) Histopathology Reporting Guide – Biopsy Specimens; Soft Tissue Sarcoma Histopathology Reporting Guide – Resection Specimens
Year:
2024
Last updated:
11 June 2024
Effective date:
1 July 2024
Country:
Australia
Programme:
Medicare Benefits Schedule (MBS)
Administering authority:
Department of Health and Aged Care
Consulted organisation:
Gastroenterological Society of Australia
Legislation:
Health Insurance Act 1973
Document type:
Policy update and item descriptor amendment notice
Medical field:
Gastroenterology
Services concerned:
Endoscopic mucosal resection and colonoscopy
MBS items affected:
32222, 32223, 32224, 32225, 32226, 32228, 32230
Explanatory notes affected:
TN.8.152, TN.8.293
Target audience:
Appropriately trained and accredited practitioners performing EMR services
Scope:
Amendments to eligibility requirements, co-claiming restrictions and billing guidance
Compliance mechanism:
MBS compliance checks and evidence requirements
Year:
Not specified
Region / Location:
Not specified
Field:
Neurobiology of swallowing, dysphagia management, pediatric feeding therapy
Document Type:
Clinical case study and therapy planning worksheet
Institution / Setting:
Clinical rehabilitation / feeding therapy context
Author:
Not specified
Patient Age:
18 months
Patient Condition:
Developmental delay following brain tumor resection with prolonged hospitalization and intubation
Clinical History:
Two-month hospital stay including two weeks of intubation; discharged with thickened liquids, soft and bite-sized diet, and nasogastric tube feeding
Primary Clinical Issues:
Aspiration of thin liquids, reduced oral intake, impaired chewing, oral motor weakness, attention and feeding behavior difficulties
Diagnostic Assessment:
Modified Barium Swallow Study (MBSS) / VFSS
Feeding Support:
NG tube with overnight continuous formula feeding
Target Areas:
Mealtime behavior, hunger regulation, oral sensory awareness, tongue lateralization, jaw strengthening, attention, self-feeding skills, straw drinking
Therapeutic Approaches:
Environmental adaptation, parent coaching, oral motor exercises, sensory stimulation, task-specific chewing practice, feeding routine structuring
Diet Level at Discharge:
Slightly thick liquids and soft & bite-sized solids
Key Symptoms:
Slow eating, distraction during meals, food pocketing, coughing with oral hygiene, aspiration of thin liquids, weak lip seal and intra-oral pressure
Version:
1.5.0.0
Protocol Posting Date:
June 2024
CAP Laboratory Accreditation Program Protocol Required Use Date:
March 2025
Authors:
Gulisa Turashvili, MD, PhD; Uma G. Krishnamurti, MD, PhD; Barbara A. Crothers, DO; Giovanna A. Giannico, MD; Krisztina Hanley, MD; Anna Plotkin, MD; Anthony N. Karnezis, MD, PhD.
Note:
Accreditation Requirements
Date of Protocol Posting:
June 2024
Date of Required Use:
March 2025
Version:
4.2.0.0
Protocol Posting Date:
June 2024
Year:
2024
Region / city:
Not specified
Topic:
Bone tumor biopsy protocols
Document type:
Protocol
Organization / institution:
Not specified
Author:
Paari Murugan, MD, FCAP; Julie C. Fanburg-Smith, MD, FCAP; Andrew Horvai, MD, PhD; Fernanda Amary, MD, PhD; Meera Hameed, MD, FCAP; Michael J. Klein, MD
Target audience:
Clinicians and pathologists involved in biopsy procedures for bone tumors
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Document type:
Supplementary table
Study focus:
Representativeness of participants with HER2-positive solid tumors
Cancer type:
HER2-Positive Solid Tumors
Countries involved:
Spain, United Kingdom, Germany
Sample size:
18 participants
Sex distribution:
4 male (22 %), 14 female (78 %)
Median age:
63 years
Age range:
46–77 years
Tumor types represented:
Breast cancer, Uterus cancer, Stomach cancer, Colorectal cancer, Paget’s disease extramammary, Gastroesophageal cancer
HER2 positivity definition:
IHC 3+
Geographical scope of epidemiological context:
Worldwide, United States, Europe
Data sources cited:
Global Cancer Observatory; SEER Program; National Cancer Institute; Eurostat; National Center for Health Statistics; JAMA Oncology
Access date of cited online sources:
3rd September 2025
Version:
5.0.0.0
Protocol Posting Date:
December 2023
CAP Laboratory Accreditation Program Protocol Required Use Date:
September 2024
Authors:
Dhanpat Jain, MD; William V. Chopp, MD; Rondell P. Graham, MBBS
Accreditation Requirements:
Core data elements required for clinical care and accreditation purposes. Optional data elements for reporting as determined by local standards.
Procedure:
Resection, biopsy, excision biopsy
Tumor Type:
Well-differentiated neuroendocrine tumor
Year:
2017
Region / City:
N/A
Topic:
Retinoblastoma, Germ Cell Tumors, Hepatoblastoma
Document Type:
Medical Case Study
Organization / Institution:
N/A
Author:
Carlos Rodriguez-Galindo, MDA
Target Audience:
Medical Professionals
Period of Action:
N/A
Approval Date:
N/A
Modification Date:
N/A